Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database

• Published in: Diabetes research and clinical practice Vol. 200; p. 110685
• Main Authors: Lo, Shih-Chang, Kornelius, Edy, Liao, Pei-Lun, Huang, Jing-Yang, Yang, Yi-Sun, Huang, Chien-Ning
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.06.2023
• Subjects: Cardiovascular disease; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - etiology; Cardiovascular Diseases - prevention & control; Diabetes Mellitus, Type 2 - chemically induced; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Heart Failure - drug therapy; Heart Failure - epidemiology; Heart Failure - prevention & control; Humans; Hypoglycemic Agents - therapeutic use; Pioglitazone - therapeutic use; Primary Prevention; SGLT2 inhibitors; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Thiazolidinedione; Type 2 diabetes; Type 2 diabetes; Cardiovascular disease; Thiazolidinedione; SGLT2 inhibitors
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2023.110685

To evaluate the effect of SGLT2is, pioglitazone, and their combination on the risk of major adverse cardiovascular events (MACE) and heart failure in type 2 diabetes mellitus (T2DM) patients without a history of cardiovascular disease. Using Taiwan National Health Insurance Research Database, we identified four groups based on medication use, including 1) both SGLT2is and pioglitazone, 2) SGLT2i, 3) pioglitazone and 4) non-study drugs (reference group). The four groups were matched by propensity score. The primary outcome was 3-point MACE, which included myocardial infarction, stroke, cardiovascular death, and the secondary outcome was incidence of heart failure. After propensity-matching, each group included 15,601 patients. Compared with the reference group, the pioglitazone/SGLT2i combination group had a significantly lower risk for MACE (aHR 0.76, 95 % CI 0.66–0.88) and heart failure (aHR 0.67, 95 % CI 0.55–0.82). Pioglitazone was associated with a lower risk of MACE (aHR 0.82, 95 % CI 0.71–0.94) and there was no difference in risk of heart failure compared with the reference group. The incidence of heart failure was significantly decreased in the SGLT2i group (aHR 0.7, 95 % CI 0.58–0.86). Combination therapy with pioglitazone and SGLT2is is an effective treatment in the primary prevention of MACE and heart failure in patients with type 2 diabetes.